title: Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment.
abstract: Serial determination of soluble CD8 (sCD8), soluble IL-2 receptors (sIL-2R), and tumor necrosis factor-alpha serum levels were performed in bone marrow transplant patients upon initiation, day 0 (D0) and at D10 of an anti-IL-2 receptor (alpha chain) monoclonal antibody (B-B10) in vivo treatment for steroid-resistant grade greater than or equal to 2 acute graft-versus-host disease (aGVHD). D0 and D10 sCD8 serum levels correlated strongly with response to B-B10 treatment (p = .003 and .001, respectively); 76% of the patients with D0 sCD8 levels less than 500 U/ml responded favorably to B-B10 treatment, versus only a 30% response if the sCD8 levels were greater than 500 U/ml (p = .02). Likewise, D0 tumor necrosis factor-alpha levels significantly correlated with subsequent response to B-B10 treatment (p = .03). D0 sIL-2R levels were not significantly different in B-B10-responsive and nonresponsive aGVHD patients. These results suggest that the serial determination of sCD8 and TNF serum levels could provide valuable predictive information as to steroid-resistant aGVHD responsiveness to anti-IL-2R treatment.
authors.affiliation: Service d'Hematologie, CHU Besancon, France.
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
authors.forename: E
authors.initials: E
authors.lastname: Racadot
authors.forename: B
authors.initials: B
authors.lastname: Lioure
authors.forename: M
authors.initials: M
authors.lastname: Delain
authors.forename: A
authors.initials: A
authors.lastname: Girard
authors.forename: J
authors.initials: J
authors.lastname: Wijdenes
authors.forename: E
authors.initials: E
authors.lastname: Plouvier
authors.forename: M
authors.initials: M
authors.lastname: Flesch
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: P
authors.initials: P
authors.lastname: Herve
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016827:CD8 Antigens; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008297:Male; D015375:Receptors, Interleukin-2 / Q000097:blood* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016827:CD8 Antigens; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha